Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma

Journal of Nuclear Medicine

Volumn 39, Issue 3, 1998, Pages 431-435

  Moon, Dae Hyuk ^b   Maddahi, Jamshid ^b   Silverman, Daniel H S ^b   Glaspy, John A ^b   Phelps, Michael E ^b   Hoh, Carl K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Breast cancer; Fluorine 18 fluorode oxyglucose; Whole body PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST BIOPSY; BREAST CARCINOMA; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SKELETAL MUSCLE; TUMOR RECURRENCE; WHOLE BODY RADIATION;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031905216     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. 18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989;13:1097-1098.
2. Wahl RL, Cody R, Hutchins G, Mudgett E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770.
3. 18F]fluoro-D-glucose. N Engl J Med 1991;324:200.
4. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216:27-34.
5. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast mass and axillary lymph node with [F-18]2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-750.
6. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer-1993;71:3920-3925.
7. 18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993;17:582-589.
8. Avril N, Jänicke F, Dose J, et al. PET imaging of breast tumors: Munich experience [Abstract]. J Nucl Med 1995;36:82P.
9. Avril N, Jänicke F, Dose J, et al. PET evaluation of axillary lymph node involvement in breast cancer patients [Abstract]. J Nucl Med 1995;36:82P-83P.
10. Wahl RL, Helvie MA, Chang AE, Andersson I. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1994;35:872-875.
11. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-2111.
12. Huovinen R, Leskinen-Kallio S, Någren K, Lehikoinen P, Ruotsalainen U, Teräs M. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 1993;67:787-791.
13. Jansson T, Westlin JE, Ahlström H, Lilia A, Langström B, Bergh J. Positron emission tomography studies with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation. J Clin Oncol 1995;13:1470-1477.
14. 18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 199;21:280-283.
15. Brinker H. Distant recurrence in breast cancer: survival expectations and first choice of chemotherapy regimen. Acta Oncol 1988;27:729-732.
16. Vahdat L, Antman K. High dose therapy for breast cancer. Blood Rev 1995;9:191-200.
17. Padgett HC, Schmidt DG, Luxen A, Bida GT, Satyamurthy N, Barrio JR. Computer-controlled radiochemical synthesis: a chemistry process control unit for the automated production of radiochemicals. Int J Rad Appl Instrum 1989;40:433-445.
18. Dahlbom M, Hoffman EJ, Hoh CK, et al. Whole-body positron emission tomography: part I. Methods and performance characteristics. J Nucl Med 1992;33:1191-1199.
19. Wienhard K, Dahlbom M, Eriksson L, et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994;18:110-118.
20. Engel H, Steinert H, Buck A, et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulation. J Nucl Med 1996;37:441-446.
21. 18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175-181.
22. 18F]FDG). Gynecol Oncol 1993;51:197-204.
23. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331-338.
24. Bohdiewicz PJ, Scott GC. Juni JE, et al. Indium-111 Oncoscint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences: early observation. Clin Nucl Med 1995;20:230-236.
25. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989;170:329-332.
26. 18F]fluoro deoxyglucose in recurrent colorectal cancer. Brit J Surg 1994;81:1666-1670.
27. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-522.
28. Valk PE. Clinical application of PET in colorectal cancer. Proceedings: the institute for clinical PET. Seventh Annual International PET Conference: 1995.
29. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-26.
30. Bailet JW, Sercarz JA, Abemayor E, Anzai Y, Lufkin RB, Hoh CK. The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patients. Laryngoscope 1995;105:135-139.
31. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1995;197:205-211.
32. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1994;191:-379-382.
33. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788-793.
34. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-709.
35. 18F]-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;132:556-562.